Should you buy ResMed (RMD)?
Updated
ResMed is a wide-moat medical devices company with a perfect Piotroski F-Score of 9 out of 9, 25% return on equity, and four consecutive earnings beats, currently experiencing a technical downtrend that creates an accumulation opportunity for investors with a 12-to-18 month horizon.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
ResMed scores 9.2 out of 10 on quality with a wide economic moat, 25% return on equity, 27% net margins, and a perfect Piotroski F-Score of 9 out of 9, placing it in the top tier of all healthcare companies evaluated on fundamental business strength. Quality breakdown | Return on equity remains above 20% and net margins stay above 24% over the next four quarters, confirming the moat is holding despite competitive pressure from connected device alternatives. | →Stable |
| CounterThe premium valuation implied by a forward price-to-earnings of 15.9 times leaves little cushion if GLP-1 weight-loss drugs reduce the obstructive sleep apnea patient population by reducing obesity-related incidence. | ||
ResMed has beaten earnings estimates in each of the last four consecutive quarters with an average positive surprise of 2.53%, demonstrating consistent delivery against consensus expectations even in a challenging competitive environment. Earnings | The beat streak extends to six or more consecutive quarters as device adoption in undiagnosed sleep apnea populations grows and software subscription revenue scales. | →Stable |
| CounterAn average surprise of only 2.53% is a thin margin; modest estimation revisions could easily convert to misses, particularly if GLP-1 drug adoption accelerates faster than management anticipates. | ||
The stock is in a confirmed downtrend with the 200-day moving average slope at -4.5% over 30 days and falling on-balance volume, but analyst consensus sees 40% upside to targets, creating a divergence between price action and fundamental valuation. Momentum breakdown | Price reclaims the 200-day moving average within 12 months and the entry target of $188.81 is reached, beginning a move toward the analyst consensus target near $243. | →Stable |
| CounterDowntrends in medical device companies can persist for extended periods when driven by secular concerns like GLP-1 disruption; catching a falling knife often requires a specific positive catalyst rather than just waiting for mean reversion. | ||
ResMed scores 9.2 out of 10 on quality with a wide economic moat, 25% return on equity, 27% net margins, and a perfect Piotroski F-Score of 9 out of 9, placing it in the top tier of all healthcare companies evaluated on fundamental business strength.
→Stable- Expectation
- Return on equity remains above 20% and net margins stay above 24% over the next four quarters, confirming the moat is holding despite competitive pressure from connected device alternatives.
CounterThe premium valuation implied by a forward price-to-earnings of 15.9 times leaves little cushion if GLP-1 weight-loss drugs reduce the obstructive sleep apnea patient population by reducing obesity-related incidence.
ResMed has beaten earnings estimates in each of the last four consecutive quarters with an average positive surprise of 2.53%, demonstrating consistent delivery against consensus expectations even in a challenging competitive environment.
→Stable- Expectation
- The beat streak extends to six or more consecutive quarters as device adoption in undiagnosed sleep apnea populations grows and software subscription revenue scales.
CounterAn average surprise of only 2.53% is a thin margin; modest estimation revisions could easily convert to misses, particularly if GLP-1 drug adoption accelerates faster than management anticipates.
The stock is in a confirmed downtrend with the 200-day moving average slope at -4.5% over 30 days and falling on-balance volume, but analyst consensus sees 40% upside to targets, creating a divergence between price action and fundamental valuation.
→Stable- Expectation
- Price reclaims the 200-day moving average within 12 months and the entry target of $188.81 is reached, beginning a move toward the analyst consensus target near $243.
CounterDowntrends in medical device companies can persist for extended periods when driven by secular concerns like GLP-1 disruption; catching a falling knife often requires a specific positive catalyst rather than just waiting for mean reversion.
▸ Show 1 more pillar▾ Show fewer
The analyst consensus price target implies 40% upside from the current $192.74, ranking the analyst upside score at 9.2 out of 10, while the forward price-to-earnings multiple of 15.9 times is attractively valued for a wide-moat healthcare compounder.
→Stable- Expectation
- The stock reaches at least $240 within 12 months as the technical downtrend reverses and the market re-rates the company on its fundamental quality.
CounterAnalyst price targets lag significantly in their response to new structural threats; the 40% upside may reflect targets set before the full impact of GLP-1 disruption was understood, and upgrades may be slow to materialize.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1ResMed scores 9.2 out of 10 on quality with a wide economic moat, 25% return on equity, 27% net margins, and a perfect Piotroski F-Score of 9 out of 9, placing it in the top tier of all healthcare companies evaluated on fundamental business strength.
Trip ifReturn on equity falls below 18% for 2 consecutive quarters, signaling the competitive moat is weakening under margin pressure.
- P2ResMed has beaten earnings estimates in each of the last four consecutive quarters with an average positive surprise of 2.53%, demonstrating consistent delivery against consensus expectations even in a challenging competitive environment.
Trip ifEPS surprise falls below 0% in at least 2 of the next 4 quarters, ending the sustained beat pattern.
- P3The stock is in a confirmed downtrend with the 200-day moving average slope at -4.5% over 30 days and falling on-balance volume, but analyst consensus sees 40% upside to targets, creating a divergence between price action and fundamental valuation.
Trip ifPrice drops below $170, more than 12% below the current $192.74, confirming the downtrend is deepening rather than stabilizing.
- P4The analyst consensus price target implies 40% upside from the current $192.74, ranking the analyst upside score at 9.2 out of 10, while the forward price-to-earnings multiple of 15.9 times is attractively valued for a wide-moat healthcare compounder.
Trip ifAnalyst consensus price target falls below $200, indicating analysts are cutting their fair value estimates by more than 20% from current levels.
How the engine reached this verdict
TrendMatrix's engine output for ResMed Inc. (RMD) is STRONG_BUY_WAIT with medium conviction, score 6.2/10 at $200.07. The engine flags WAIT: the structural case holds but the entry-asymmetry math improves at lower prices.
The engine's suggested entry zone is $183.79, currently 8.9% above entry. Target $234.54, stop $173.75, asymmetric R:R 3.88. The WAIT designation reflects entry-discipline framing — chasing into the current zone compresses asymmetry, which is why the engine separates WAIT from NOW. The engine's sizing output: 1.5% of portfolio at this asymmetry level (high-conviction tier).
On the bull side: Strong earnings beat streak (4/4); High-quality business; Wide economic moat. On the bear side: Below 200-MA, MA slope -4.9%/30d (confirmed downtrend).
BUY_NOW requires asymmetry R:R climbing above the 2.5 conviction threshold (currently 3.88); the verdict flips to HOLD if overall score deteriorates by ~0.7.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates RMD — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (4/4)
- ▸High-quality business
- ▸Wide economic moat
Bear case
- ▸Below 200-MA, MA slope -4.9%/30d (confirmed downtrend)